<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK548705" /><meta name="ncbi_domain" content="livertox" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK548705/" /><meta name="ncbi_pagename" content="Carbapenems - LiverTox - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Carbapenems - LiverTox - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]" /><meta name="citation_title" content="Carbapenems" /><meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="citation_date" content="2017/01/15" /><meta name="citation_pmid" content="31644015" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK548705/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Carbapenems" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="DC.Date" content="2017/01/15" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK548705/" /><meta name="description" content="The carbapenems are beta lactam antibiotics which have a broad spectrum of activity against many gram-positive and gram-negative, aerobic and anaerobic organisms. The carbapenems, like other beta lactam antibiotics, bind to critical penicillin-binding proteins, disrupting the growth and structural integrity of bacterial cell walls. Carbapenems have a fused beta lactam ring that is resistant to most beta lactamases. The carbapenems have excellent activity against streptococci, enterococci, staphylococcci, listeria, enterobacteriaceae, and many pseudomonas, bacteroides and acinetobacter species. However, most methicillin-resistant staphylococci are also resistant to carbapenems. Carbapenems have a safety profile similar to that of other beta lactam antibiotics such as the cephalosporins and the penicillins. The most common adverse effects are injection site reactions, diarrhea, nausea, vomiting, skin rash and pruritus." /><meta name="og:title" content="Carbapenems" /><meta name="og:type" content="book" /><meta name="og:description" content="The carbapenems are beta lactam antibiotics which have a broad spectrum of activity against many gram-positive and gram-negative, aerobic and anaerobic organisms. The carbapenems, like other beta lactam antibiotics, bind to critical penicillin-binding proteins, disrupting the growth and structural integrity of bacterial cell walls. Carbapenems have a fused beta lactam ring that is resistant to most beta lactamases. The carbapenems have excellent activity against streptococci, enterococci, staphylococcci, listeria, enterobacteriaceae, and many pseudomonas, bacteroides and acinetobacter species. However, most methicillin-resistant staphylococci are also resistant to carbapenems. Carbapenems have a safety profile similar to that of other beta lactam antibiotics such as the cephalosporins and the penicillins. The most common adverse effects are injection site reactions, diarrhea, nausea, vomiting, skin rash and pruritus." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK548705/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/livertox/Carbapenems/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK548705/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8895FB046649210000000005330177.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="protfam">Protein Family Models</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All Drug Records" href="/books/n/livertox/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" alt="Cover of LiverTox" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK548705_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK548705_dtls__"><div>Bethesda (MD): <a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>; 2012-.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/livertox/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search this book" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search this book" submit="false" style="padding: 0.1em 0.4em;" /></div></form></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Carbamazepine/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Carbinoxamine/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK548705_"><span class="title" itemprop="name">Carbapenems</span></h1><p class="small">Last Update: <span itemprop="dateModified">January 15, 2017</span>.</p></div><div class="body-content whole_rhythm" itemprop="text"><div id="Carbapenems.OVERVIEW"><h2 id="_Carbapenems_OVERVIEW_">OVERVIEW</h2><p>The carbapenems are beta lactam antibiotics which have a broad spectrum of activity against many gram-positive and gram-negative, aerobic and anaerobic organisms. The carbapenems, like other beta lactam antibiotics, bind to critical penicillin-binding proteins, disrupting the growth and structural integrity of bacterial cell walls. Carbapenems have a fused beta lactam ring that is resistant to most beta lactamases. The carbapenems have excellent activity against streptococci, enterococci, staphylococcci, listeria, enterobacteriaceae, and many pseudomonas, bacteroides and acinetobacter species. However, most methicillin-resistant staphylococci are also resistant to carbapenems. Carbapenems have a safety profile similar to that of other beta lactam antibiotics such as the cephalosporins and the penicillins. The most common adverse effects are injection site reactions, diarrhea, nausea, vomiting, skin rash and pruritus.</p><p>The carbapenems (kar" ba pen' ems) that are currently available in the United States (with pronunciation, year of approval and initial brand name) include imipenem (im" i pen' em: 1985, Primaxin), meropenem (mer" oh pen' em: 1996, Merrem), ertapenem (er" ta pen' em: 2001, Invanz) and doripenem (dor" i pen' em: 2008, Doribax). All four agents are poorly absorbed orally and require parenteral administration. Imipenem is given with cilastatin (sye" la stat' in), which inhibits the renal metabolism of imipenem and prolongs its half-life. Imipenem is noted for its dose dependent gastrointestinal side effects as compared to the other carbapenems.</p><p>Most carbapenems have been reported to cause transient, mild-to-moderate, and asymptomatic increases in serum aminotransferase levels that rapidly resolve once therapy is stopped. In addition, there have been rare reports of cholestatic liver injury arising during or shortly after carbapenem therapy, often in patients with multiple other medical problems and other causes for liver disease (parenteral nutrition, sepsis). The carbapenems are excreted largely unchanged in the urine with minimal hepatic metabolism, which may be the reason why clinically significant hepatotoxicity with jaundice from the carbapenems is rare.</p><p>Each of the carbapenems is discussed separately although references to hepatotoxicity are given together below in this Overview section. The following are links to each specific drug record.</p><ul><li class="half_rhythm"><div><a href="/books/n/livertox/Doripenem/">Doripenem</a></div></li><li class="half_rhythm"><div><a href="/books/n/livertox/Ertapenem/">Ertapenem</a></div></li><li class="half_rhythm"><div><a href="/books/n/livertox/Imipenemcilastatin/">Imipenem</a></div></li><li class="half_rhythm"><div><a href="/books/n/livertox/Meropenem/">Meropenem</a></div></li></ul></div><div id="Carbapenems.CHEMICAL_FORMULAS_AND_STRUCT"><h2 id="_Carbapenems_CHEMICAL_FORMULAS_AND_STRUCT_">CHEMICAL FORMULAS AND STRUCTURES</h2><div id="Carbapenems.T1" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548705/table/Carbapenems.T1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Carbapenems.T1_lrgtbl__"><table><tbody><tr><th id="hd_b_Carbapenems.T1_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">DRUG</th><th id="hd_b_Carbapenems.T1_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CAS REGISTRY NO</th><th id="hd_b_Carbapenems.T1_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_b_Carbapenems.T1_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">STRUCTURE</th></tr><tr><td headers="hd_b_Carbapenems.T1_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Doripenem</td><td headers="hd_b_Carbapenems.T1_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">148016-81-3</td><td headers="hd_b_Carbapenems.T1_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">C15-H24-N4-O6-S2</td><td headers="hd_b_Carbapenems.T1_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"><div class="graphic"><img src="/books/NBK548705/bin/clip_image002_005.jpg" alt="Image clip_image002_005.jpg" /></div></td></tr><tr><td headers="hd_b_Carbapenems.T1_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Ertapenem</td><td headers="hd_b_Carbapenems.T1_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/135106916" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">153832-46-3</a></td><td headers="hd_b_Carbapenems.T1_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">C22-H25-N3-O7-S</td><td headers="hd_b_Carbapenems.T1_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"><div class="graphic"><img src="/books/NBK548705/bin/Ertapenem_Structure_000.jpg" alt="Ertapenem chemical structure" /></div></td></tr><tr><td headers="hd_b_Carbapenems.T1_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Imipenem</td><td headers="hd_b_Carbapenems.T1_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/135012513" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">74431-23-5</a></td><td headers="hd_b_Carbapenems.T1_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">C12-H17-N3-O4-S.H2O</td><td headers="hd_b_Carbapenems.T1_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"><div class="graphic"><img src="/books/NBK548705/bin/Imipenem_Structure_000.jpg" alt="Imipenem chemical structure" /></div></td></tr><tr><td headers="hd_b_Carbapenems.T1_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Meropenem</td><td headers="hd_b_Carbapenems.T1_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/135017839" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">119478-56-7</a></td><td headers="hd_b_Carbapenems.T1_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">C17-H25-N3-O5-S.H2-O</td><td headers="hd_b_Carbapenems.T1_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"><div class="graphic"><img src="/books/NBK548705/bin/Meropenem_Structure_000.jpg" alt="Meropenem chemical structure" /></div></td></tr></tbody></table></div></div></div><div id="Carbapenems.ANNOTATED_BIBLIOGRAPHY"><h2 id="_Carbapenems_ANNOTATED_BIBLIOGRAPHY_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: 15 January 2017</p><ul class="first-line-outdent"><li><div class="bk_ref" id="Carbapenems.R1">Zimmerman HJ. Hepatic injury from the treatment of infectious and parasitic diseases. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, pp. 589-637.<div><i>(Expert review of liver injury due to antimicrobial agents published in 1999, imipenem-cilastin is listed in a table as a cause of serum enzyme elevations only, the other carbapenems are not mentioned).</i></div></div></li><li><div class="bk_ref" id="Carbapenems.R2">Moseley RH. Other beta-lactam antibiotics. Hepatotoxicity of antimicrobials and antifungal agents. In, Kaplowitz N, DeLeve LD, eds. Drug-induced Liver Disease. 3rd edition. Amsterdam: Elsevier, 2013, pp. 466.<div><i>(Expert review of antibiotic induced liver injury mentions 2 case reports of liver injury from carbapenems).</i></div></div></li><li><div class="bk_ref" id="Carbapenems.R3">Petri WA Jr. Penicillins, cephalosporins, and other betalactam antibiotics. In, Brunton LL, Chabner BA, Knollman BC, eds. Goodman &#x00026; Gilman&#x02019;s the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill, 2011, pp. 1477-1504.<div><i>(Textbook of pharmacology and therapeutics).</i></div></div></li><li><div class="bk_ref" id="Carbapenems.R4">Calandra GB, Ricci FM, Wang C, Brown KR. Safety and tolerance comparison of imipenem-cilastatin to cephalothin and cefazolin. J Antimicrob Chemother 1983; 12 (Suppl D): 125-31.  [<a href="/pubmed/6583195" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6583195</span></a>]<div><i>(Summary of two randomized control trials found AST elevations were more common with imipenem/cilastatin [8 of 208 patients] than with cephalosporins [none of 196]; liver tests were only transiently abnormal and none were associated with symptoms or required drug discontinuation).</i></div></div></li><li><div class="bk_ref" id="Carbapenems.R5">Chiodini PL, Geddes AM, Smith EG, Conlon CP, Farrell ID. Imipenem/cilastatin in the treatment of serious bacterial infections. Rev Infect Dis 1985; 7 (Suppl 3): S490-5.  [<a href="/pubmed/3901212" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3901212</span></a>]<div><i>(45 patients given imipenem/cilastatin 2 or 4 g/day four times a day for 1-24 days; phlebitis was common, two adverse events were attributed to therapy&#x02013;both with mild abnormalities of liver tests, but not explained further).</i></div></div></li><li><div class="bk_ref" id="Carbapenems.R6">Drusano GL, Standiford HC, Bustamante CI, Rivera G, Forrest A, Leslie J, Tatem B, et al. Safety and tolerability of multiple doses of imipenem/cilastatin. Clin Pharmacol Ther 1985; 37: 539-43.  [<a href="/pubmed/3886256" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3886256</span></a>]<div><i>(Placebo controlled trial in 12 normal volunteers given imipenem/cilastatin iv for 10 days with laboratory tests pre-, 4 times during and once after; elevated ALT levels occurred in 2 of 6 patients in both groups, but were transient and asymptomatic).</i></div></div></li><li><div class="bk_ref" id="Carbapenems.R7">Calandra GB, Wang C, Aziz M, Brown KR. The safety profile of imipenem/cilastatin: worldwide clinical experience based on 3470 patients. J Antimicrob Chemother 1986; 18 (Suppl E): 193-202.  [<a href="/pubmed/3469194" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3469194</span></a>]<div><i>(Combined results of studies in 3470 patients receiving imipenem/cilastatin for up to 14 days; ALT elevations occurred in 5.3%, but most were transient and asymptomatic; 3 patients [0.1%] developed &#x0201c;marked changes in liver function tests and developed icterus during trials of imipenem/cilastatin necessitating its discontinuation. These changes resolved with no long-term sequelae&#x0201d;).</i></div></div></li><li><div class="bk_ref" id="Carbapenems.R8">Garau J, Calandra GB. Intramuscular imipenem/cilastatin in multiple-dose treatment regimens: review of the worldwide clinical experience. Chemotherapy 1991; 37 (Suppl 2): 44-52.  [<a href="/pubmed/1879187" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1879187</span></a>]<div><i>(Review of 32 studies in 686 patients of intramuscular imipenem/cilastatin; rates of adverse events were similar to those reported with iv administration, ALT elevations in 1.3%, no mention of clinically apparent liver injury).</i></div></div></li><li><div class="bk_ref" id="Carbapenems.R9">Lami JL, Wilson SE, Hopkins JA. Adjunctive antimicrobials in surgery of soft tissue infections: evaluation of cephalosporins and carbapenems. Am Surg 1991; 57: 769-74.  [<a href="/pubmed/1746792" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1746792</span></a>]<div><i>(Trial of meropenem [n=26] vs imipenem [n=26]; one patient on meropenem developed abnormal liver tests without further comment).</i></div></div></li><li><div class="bk_ref" id="Carbapenems.R10">Schreiber C, May B. [Cholestasis in imipenem/cilastatin treatment] Z Gastroenterol 1993; 31 (Suppl 2): 76-7. German.  [<a href="/pubmed/7483723" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7483723</span></a>]<div><i>(Abstract only: Cholestatic hepatitis arising after imipenem/cilastatin therapy; resolution in 4 weeks).</i></div></div></li><li><div class="bk_ref" id="Carbapenems.R11">Drusano G. Meropenem: laboratory and clinical data. Clin Microbiol Infect 1997; 3 (Suppl 4): S51-S59.  [<a href="/pubmed/11869241" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11869241</span></a>]<div><i>(Review of structure, pharmacology and clinical efficacy of meropenem; similar success rates as with imipenem, cephalosporin-aminoglycoside combinations; no discussion of adverse events).</i></div></div></li><li><div class="bk_ref" id="Carbapenems.R12">Alverez Lerma F, Gil CL. [Clinical experience with meropenem in the treatment of severe infections in critically ill patients.] Rev Esp Quimioter 1998; 11: 229-37. Spanish.  [<a href="/pubmed/9795309" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9795309</span></a>]<div><i>(A study of 178 patients who received meropenem for various infections; 2 patients [1%] developed transiently abnormal ALT levels).</i></div></div></li><li><div class="bk_ref" id="Carbapenems.R13">Quattropani C, Schneider M, Helbling A, Zimmermann A, Kr&#x000e4;henb&#x000fc;hl S. Cholangiopathy after short-term administration of piperacillin and imipenem/cilastatin. Liver 2001; 21: 213-6. <em>(</em> [<a href="/pubmed/11422785" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11422785</span></a>]<div><i>20 year old man with severe trauma developed jaundice 2 weeks after a single dose of piperacillin and 3 days of imipenem/cilastatin [bilirubin 0.9 rising to 4.7 mg/dL, ALT 345-669 U/L, Alk P 201 to 599 U/L], resolving over the next 2 months, unclear whether related to piperacillin, cilastatin or imipenem or to sepsis).</i></div></div></li><li><div class="bk_ref" id="Carbapenems.R14">Graham DR, Lucasti C, Malafaia O, Nichols RL, Holtom P, Perez NQ, McAdams A, et al. Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study. Clin Infect Dis 2002; 34: 1460-8.  [<a href="/pubmed/12015692" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12015692</span></a>]<div><i>(Randomized controlled trial of ertapenem vs piperacillin-tazobactam in 540 patients; ALT elevations in 4.3% [40-271 U/L] of ertapenem vs 3.7% [40-271 U/L] in piper/tazo-recipients, all resolving after stopping ertapenem).</i></div></div></li><li><div class="bk_ref" id="Carbapenems.R15">Teppler H, Gesser RM, Friedland IR, Woods GL, Meibohm A, Herman G, Mistry G, et al. Safety and tolerability of ertapenem. J Antimicrob Chemother 2004; 53 (Suppl 2): ii75-81.  [<a href="/pubmed/15150186" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15150186</span></a>]<div><i>(Summary of safety studies in 240 healthy volunteers and 2046 patients in Phase II and III trials of ertapenem; side effects were similar to those of comparative agents including ceftriazone and piperacillin/tazobactam; mild-to-moderate ALT elevations occurred in 8.3-8.8% of ertapenem, compared to 6.9-7.3% of comparator-recipients treated for 1 to 28 days; all abnormalities returned to normal in post-therapy follow-up).</i></div></div></li><li><div class="bk_ref" id="Carbapenems.R16">Blumer JL, Saiman L, Konstan MW, Melnick D. The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis. Chest 2005; 128: 2336-46.  [<a href="/pubmed/16236892" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16236892</span></a>]<div><i>(Randomized trial of meropenem vs ceftazidime [both with tobramycin] in 121 patients with cystic fibrosis; ALT elevations occurred in 10-12% of patients in both groups; one patient was withdrawn from meropenem because of abnormal ALT, AST and Alk P levels attributed to therapy).</i></div></div></li><li><div class="bk_ref" id="Carbapenems.R17">Zhanel GG, Johanson C, Embil JM, Noreddin A, Gin A, Vercaigne L, Hoban DJ. Ertapenem: review of a new carbapenem. Expert Rev Anti Infect Ther 2005; 3: 23-39.  [<a href="/pubmed/15757455" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15757455</span></a>]<div><i>(Extensive review of ertapenem pharmacology, efficacy and safety; largely quotes safety results from Teppler et al. [2004]).</i></div></div></li><li><div class="bk_ref" id="Carbapenems.R18">Linden P. Safety profile of meropenem: an updated review of over 6,000 patients treated with meropenem. Drug Saf 2007; 30: 657-68.  [<a href="/pubmed/17696578" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17696578</span></a>]<div><i>(Extensive review of studies of safety of meropenem in phase III studies reported ALT elevations in 5.2% of meropenem recipients [n=6308] compared to 4.2% with cephalosporins, 3.2% with imipenem/cilastatin and 8.2% with clindamycin-aminoglycosides; no mention of hepatitis or jaundice).</i></div></div></li><li><div class="bk_ref" id="Carbapenems.R19">Zhanel GG, Wiebe R, Dilay L, et al. Comparative review of the carbapenems. Drugs 2007; 67: 1027-52.  [<a href="/pubmed/17488146" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17488146</span></a>]<div><i>(Review of pharmacology, efficacy and safety of 3 carbapenems &#x0201c;Like other &#x000df;-lactams, imipenem/cilastatin, meropenem and ertapenem can affect various laboratory tests including mild-to-moderate, transient increases in hepatic enzymes.&#x0201d;). </i></div></div></li><li><div class="bk_ref" id="Carbapenems.R20">Doripenem (Doribax)--a new parenteral carbapenem. Med Lett Drugs Ther 2008; 50 (1278): 5-7.  [<a href="/pubmed/18219262" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18219262</span></a>]<div><i>(Concise review of the antibacterial activity, clinical efficacy, safety and costs of doripenem shortly after its approval in the US; mentions side effects of headaches, nausea, diarrhea, rash, injection site phlebitis and hypersensitivity reactions; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Carbapenems.R21">Lucasti C, Jasovich A, Umeh O, Jiang J, Kaniga K, Friedland I. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study. Clin Ther 2008; 30: 868-83.  [<a href="/pubmed/18555934" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18555934</span></a>]<div><i>(Among 476 patients with complicated intraabdominal infections treated with iv doripenem or meropenem, cure rates [86% vs 85%] and adverse event rates [83% vs 78%] were similar, hepatic enzyme elevations occurred in 2 [0.9%] vs 6 [2.5%] patients, and no serious adverse event was considered drug related).</i></div></div></li><li><div class="bk_ref" id="Carbapenems.R22">R&#x000e9;a-Neto A, Niederman M, Lobo SM, Schroeder E, Lee M, Kaniga K, Ketter N, et al. Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study. Curr Med Res Opin 2008; 24: 2113-26.  [<a href="/pubmed/18549664" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18549664</span></a>]<div><i>(Among 448 patients with nosocomial pneumonia treated with iv doripenem or piperacillin/tazobactam for 7 to 14 days, both cure rates and adverse event rates were similar, ALT elevations arising in 1.8% vs 0.9% of patients).</i></div></div></li><li><div class="bk_ref" id="Carbapenems.R23">Chastre J, Wunderink R, Prokocimer P, Lee M, Kaniga K, Friedland I. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med 2008; 36: 1089-96.  [<a href="/pubmed/18379232" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18379232</span></a>]<div><i>(Among 531 patients with ventilator associated pneumonia treated wtih doripenem or imipenem for 7-14 days, both response and adverse event rates were similar and "hepatic enzyme increased" was reported in 4.6% on doripenem and 2.3% on imipenem; no mention of clinically apparent liver injury or liver related deaths).</i></div></div></li><li><div class="bk_ref" id="Carbapenems.R24">Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, Yang H, Rochon J; Drug Induced Liver Injury Network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008; 135: 1924-34.  [<a href="/pmc/articles/PMC3654244/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3654244</span></a>] [<a href="/pubmed/18955056" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18955056</span></a>]<div><i> (Among 300 cases of drug induced liver disease in the US collected from 2004 to 2008, one was linked to imipenem-cilastatin, but was judged as only possibly related, the patient developing elevated Alk P [peak 638 U/L] and bilirubin [2.3 mg/dL] during a bout of alcoholic pancreatitis and while receiving imipenem).</i></div></div></li><li><div class="bk_ref" id="Carbapenems.R25">Redman R, File TM Jr. Safety of intravenous infusion of doripenem. Clin Infect Dis 2009; 49 Suppl 1: S28-35.  [<a href="/pubmed/19619019" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19619019</span></a>]<div><i>(Review of safety data from 1817 patients in 7 clinical trials of iv doripenem and 1325 patients receiving comparator drugs, reported similar rates of side effects with doripenem as with other arms; diarrhea in 9%, headache 10%, nausea 8%, phlebitis 6%, rash in 4%, hypersensitivity reacitons 0.7%, ALT elevations 1.1%, jaundice and ALT elevations in 0.8%, but no episodes of acute liver failure).</i></div></div></li><li><div class="bk_ref" id="Carbapenems.R26">Schumaker AL, Okulicz JF. Meropenem-induced vanishing bile duct syndrome. Pharmacotherapy 2010; 30: 335e-338e.  [<a href="/pubmed/20812433" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20812433</span></a>]<div><i>(60 year old woman developed jaundice 3 weeks after starting meropenem [bilirubin 11.2 mg/dL, ALT 83 U/L, Alk P 1467 U/L], with biopsy showing bile duct loss and subsequent prolonged jaundice and pruritus).</i></div></div></li><li><div class="bk_ref" id="Carbapenems.R27">Goto M, Shimizu F, Takeo N, Okamoto O, Katagiri K, Ikewaki J, Ogata M, et al. Drug-induced hypersensitivity syndrome due to carbapenem antibiotics. J Dermatol 2010; 37: 374-7.  [<a href="/pubmed/20507410" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20507410</span></a>]<div><i>(64 year old man with lymphoma on chemotherapy developed rash, fever, lymphadenopathy and liver injury while on multiple drugs including loxoprofen, SMZ/TMP, ciprofloxacin, zolpidem and meropenem and imipenem-cilastin [bilirubin not given, ALT 148 U/L, Alk P 427 U/L], also associated with CMV and HHV-6 viremia, lymphocyte stimulation tests were positive to carbapenem antibiotics and not to other agents, resolving with prednisone therapy).</i></div></div></li><li><div class="bk_ref" id="Carbapenems.R28">Reuben A, Koch DG, Lee WM; Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 2010; 52: 2065-76.  [<a href="/pmc/articles/PMC3992250/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3992250</span></a>] [<a href="/pubmed/20949552" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20949552</span></a>]<div><i>(Among 1198 patients with acute liver failure enrolled in a US prospective study between 1998 and 2007, 133 were attributed to drug induced liver injury but none were due to carbenepenems). </i></div></div></li><li><div class="bk_ref" id="Carbapenems.R29">Chahine EB, Ferrill MJ, Poulakos MN. Doripenem: a new carbapenem antibiotic. Am J Health Syst Pharm 2010; 67: 2015-24.  [<a href="/pubmed/21098373" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21098373</span></a>]<div><i>(Review of the chemistry, antibacterial activity, pharmacology, clinical efficacy and safety of doripenem mentions the most common side effects as being heachache, insomnia, gastrointestinal upset, and phlebitis; and, that hepatic enzyme elevations occur in 0.8-4.6% of treated subjects).</i></div></div></li><li><div class="bk_ref" id="Carbapenems.R30">Redman R, Damiao R, Kotey P, Kaniga K, Davies T, Naber KG. Safety and efficacy of intravenous doripenem for the treatment of complicated urinary tract infections and pyelonephritis. J Chemother 2010; 22: 384-91.  [<a href="/pubmed/21303745" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21303745</span></a>]<div><i>(Among 799 patients with complicated urinary tract infections treated with iv doripenem and 372 with levofloxacin, both response and adverse event rates were similar; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Carbapenems.R31">Tazuma S, Igarashi Y, Inui K, Ohara H, Tsuyuguchi T, Ryozawa S; BTI Therapy Research Group. Clinical efficacy of i.v. doripenem, a new class of carbapenem, in patients with biliary tract infection: A multicenter trial. Hepatol Res 2011; 41: 340-9.  [<a href="/pubmed/21426451" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21426451</span></a>]<div><i>(Among 119 patients with acute biliary tract infections treated with iv doripenem for 2-17 days, the response rate was 92% and only 6 patients had adverse events, none were serious, 3 were liver related and 2 led to early withdrawal with subsequent resolution).</i></div></div></li><li><div class="bk_ref" id="Carbapenems.R32">Kwon H, Lee SH, Kim SE, Lee JH, Jee YK, Kang HR, Park BJ, Park JW, Hong CS. Spontaneously reported hepatic adverse drug events in Korea: multicenter study. J Korean Med Sci 2012; 27: 268-73.  [<a href="/pmc/articles/PMC3286773/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3286773</span></a>] [<a href="/pubmed/22379337" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22379337</span></a>]<div><i>(Summary of 2 years of adverse event reporting in Korea; of 9360 reports, 567 were liver related, including 9 [1.6%] attributed to carbapenems).</i></div></div></li><li><div class="bk_ref" id="Carbapenems.R33">Bj&#x000f6;rnsson ES, Bergmann OM, Bj&#x000f6;rnsson HK, Kvaran RB, Olafsson S. Incidence, presentation and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 2013; 144: 1419-25.  [<a href="/pubmed/23419359" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23419359</span></a>]<div><i>(In a population based study of drug induced liver injury from Iceland, 96 cases were identified over a 2 year period, but none were attributed to carbenepenems).</i></div></div></li><li><div class="bk_ref" id="Carbapenems.R34">Hornik CP, Herring AH, Benjamin DK Jr, Capparelli EV, Kearns GL, van den Anker J, Cohen-Wolkowiez M, et al.; Best Pharmaceuticals for Children Act-Pediatric Trials Network. Adverse events associated with meropenem versus imipenem/cilastatin therapy in a large retrospective cohort of hospitalized infants. Pediatr Infect Dis J 2013; 32: 748-53. (Analysis of adverse event reports from 322 neonatal intensive care units between 1997 to 2010 included reports of ALT elevations above 100 U/L in 2% of imipenem vs 7% of meropenem treated neonates, but there were no liver related severe adverse events). [<a href="/pmc/articles/PMC3708263/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3708263</span></a>] [<a href="/pubmed/23838776" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23838776</span></a>]</div></li><li><div class="bk_ref" id="Carbapenems.R35">Hern&#x000e1;ndez N, Bessone F, S&#x000e1;nchez A, di Pace M, Brahm J, Zapata R, A Chirino R, et al. Profile of idiosyncratic drug induced liver injury in Latin America. An analysis of published reports. Ann Hepatol 2014; 13: 231-9.  [<a href="/pubmed/24552865" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24552865</span></a>]<div><i> (Systematic review of literature of drug induced liver injury in Latin American countries published from 1996 to 2012 identified 176 cases, the most common implicated agents being nimesulide [n=53: 30%], cyproterone [n=18] and nitrofurantoin [n=17]; no carbapenems were listed).</i></div></div></li><li><div class="bk_ref" id="Carbapenems.R36">Cannavino CR, Castaneda-Ruiz B, Redman R, Go O, Cirillo I, Barauskas V, Senatorova G, et al. Safety and tolerability of doripenem in hospitalized children With complicated intra-abdominal infection, complicated urinary tract infections and pneumonia. Pediatr Infect Dis J 2015; 34: 1264-7.  [<a href="/pubmed/26226440" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26226440</span></a>]<div><i>(Among 88 children with severe bacterial infections treated with iv doripenem or a comparator antibiotic, serious adverse event rates were similar and ALT elevations occurred in 3 of 66 [4.5%] vs none of 22 [0%], but none developed clinically apparent liver injury).</i></div></div></li><li><div class="bk_ref" id="Carbapenems.R37">Tazuma S, Igarashi Y, Inui K, Ohara H, Tsuyuguchi T, Ryozawa S; BTI Therapy Research Group. Clinical efficacy of intravenous doripenem in patients with acute biliary tract infection: a multicenter, randomized, controlled trial with imipenem/cilastatin as comparator. J Gastroenterol 2015; 50: 221-9.  [<a href="/pubmed/24795092" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24795092</span></a>]<div><i> (Among 127 patients with acute biliary tract infections treated with doripenem [D] or imimpenem/cilastatin [I/C] for 3-21 days, response rates were similar and the only adverse drug reactions were watery diarrhea [D], hypersensivity rash [D] and pseudomembraneous colitis [I/C] in one patient each, no mention of ALT elevations).</i></div></div></li><li><div class="bk_ref" id="Carbapenems.R38">Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, et al.; United States Drug Induced Liver Injury Network. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study. Gastroenterology 2015; 148: 1340-52.  [<a href="/pmc/articles/PMC4446235/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4446235</span></a>] [<a href="/pubmed/25754159" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25754159</span></a>]<div><i>(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, 323 [36%] were attributed to antibiotics, but only one to a carbapenem [meropenem]).</i></div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div><div class="small"><span class="label">Bookshelf ID: NBK548705</span><span class="label">PMID: <a href="/pubmed/31644015" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">31644015</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Carbamazepine/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Carbinoxamine/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK548705&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK548705/?report=reader">PubReader</a></li><li><a href="/books/NBK548705/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK548705" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK548705" style="display:none" title="Cite this Page"><div class="bk_tt">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.  Carbapenems. [Updated 2017 Jan 15].<span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK548705/pdf/Bookshelf_NBK548705.pdf">PDF version of this page</a> (122K)</li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Bulk Download</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://ftp.ncbi.nlm.nih.gov/pub/litarch/29/31/" ref="pagearea=source-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Bulk download LiverTox data from FTP</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Overviews</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/intro/">Introduction</a></li><li><a href="/books/n/livertox/Causality/">Causality</a></li><li><a href="/books/n/livertox/ClinicalCourse/">Clinical Course</a></li><li><a href="/books/n/livertox/ClinicalOutcome/">Clinical Outcomes</a></li><li><a href="/books/n/livertox/ImmuneFeatures/">Immune Features</a></li><li><a href="/books/n/livertox/DrugCategory/">Likelihood Scale</a></li><li><a href="/books/n/livertox/Phenotypes_intro/">Phenotypes</a></li><li><a href="/books/n/livertox/Severity/">Severity Grading</a></li><li><a href="/books/n/livertox/CaseReport/">Writing a Case Report</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Support Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/">LiverTox Homepage</a></li><li><a href="/books/n/livertox/aboutus/">About LiverTox</a></li><li><a href="/books/n/livertox/editorsandreviewers/">Editors and Review Committee</a></li><li><a href="/books/n/livertox/alert/">Meetings and News</a></li><li><a href="/books/n/livertox/abbreviation/">Abbreviations Used</a></li><li><a href="/books/n/livertox/glossary/">Glossary</a></li><li><a href="/books/n/livertox/resource/">Information Resources</a></li><li><a href="/books/n/livertox/disclaimer/">User/Medical Advice Disclaimer</a></li><li><a href="/books/n/livertox/Contactus/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>OTHER REFERENCE LINKS</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;pubmedfilters=true&amp;term=Carbapenems+AND+Human%5BMH%5D+AND+(drug+induced+liver+injury+OR+jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%221900/1/1%22%5BEDat%5D%3A%222999/12/31%22%5BEDat%5D)" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Recent References on Carbapenems: from PubMed.gov</a></li><li><a href="https://clinicaltrials.gov/ct2/results?term=carbapenems" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Trials on Carbapenems: from ClinicalTrials.gov</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=4858056" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pcsubstance&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pcsubstance&amp;IdsFromResult=4858056" ref="log$=recordlinks">PubChem Substance</a><div class="brieflinkpop offscreen_noflow">Related PubChem Substances</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=4858056" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31644018" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Imipenem-Cilastatin</a><span class="source">[LiverTox: Clinical and Researc...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Imipenem-Cilastatin<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/17488146" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Comparative review of the carbapenems.</a><span class="source">[Drugs. 2007]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Comparative review of the carbapenems.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Zhanel GG, Wiebe R, Dilay L, Thomson K, Rubinstein E, Hoban DJ, Noreddin AM, Karlowsky JA. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Drugs. 2007; 67(7):1027-52. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/30712199" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.</a><span class="source">[Drugs. 2019]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Zhanel GG, Golden AR, Zelenitsky S, Wiebe K, Lawrence CK, Adam HJ, Idowu T, Domalaon R, Schweizer F, Zhanel MA, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Drugs. 2019 Feb; 79(3):271-289. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/10221472" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Carbapenems and monobactams: imipenem, meropenem, and aztreonam.</a><span class="source">[Mayo Clin Proc. 1999]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Carbapenems and monobactams: imipenem, meropenem, and aztreonam.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Hellinger WC, Brewer NS. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Mayo Clin Proc. 1999 Apr; 74(4):420-34. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/11922861" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Recent developments in carbapenems.</a><span class="source">[Expert Opin Investig Drugs. 2002]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Recent developments in carbapenems.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Bonfiglio G, Russo G, Nicoletti G. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Expert Opin Investig Drugs. 2002 Apr; 11(4):529-44. </em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=31644015" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=31644015" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=60467b0db1d385378ae48c65">Carbapenems - LiverTox</a><div class="ralinkpop offscreen_noflow">Carbapenems - LiverTox<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2021-03-08T14:29:18-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@9.2&amp;Host=portal101&amp;ncbi_phid=CE8895FB046649210000000005330177&amp;ncbi_session=CE8895FB0467B0D1_1331SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK548705%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK548705&amp;ncbi_domain=livertox&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK548705/&amp;ncbi_pagename=Carbapenems - LiverTox - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8895FB0467B0D1_1331SID /projects/books/PBooks@9.2 portal101 v4.1.r621975 Fri, Dec 18 2020 02:56:50 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>